Legal & General Group’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $61.8M | Buy |
883,075
+132,234
| +18% | +$6.84M | 0.01% | 602 |
|
|
2026
Q1 | $38.1M | Sell |
750,841
-186,129
| -20% | -$8.68M | 0.01% | 668 |
|
|
2025
Q4 | $27.6M | Sell |
936,970
-64,289
| -6% | -$1.75M | 0.01% | 749 |
|
|
2025
Q3 | $25.9M | Sell |
1,001,259
-424,905
| -30% | -$11.9M | 0.01% | 775 |
|
|
2025
Q2 | $39.3M | Sell |
1,426,164
-845,459
| -37% | -$22.3M | 0.01% | 667 |
|
|
2025
Q1 | $64.4M | Buy |
2,271,623
+114,502
| +5% | +$4.06M | 0.02% | 579 |
|
|
2024
Q4 | $89.7M | Buy |
2,157,121
+69,552
| +3% | +$3.32M | 0.02% | 527 |
|
|
2024
Q3 | $140M | Buy |
2,087,569
+9,978
| +0.5% | +$916K | 0.04% | 429 |
|
|
2024
Q2 | $247M | Sell |
2,077,591
-260,124
| -11% | -$32.9M | 0.07% | 287 |
|
|
2024
Q1 | $249M | Sell |
2,337,715
-26,357
| -1% | -$2.66M | 0.07% | 282 |
|
|
2023
Q4 | $235M | Sell |
2,364,072
-7,702
| -0.3% | -$648K | 0.07% | 290 |
|
|
2023
Q3 | $245M | Sell |
2,371,774
-66,134
| -3% | -$7.38M | 0.09% | 256 |
|
|
2023
Q2 | $296M | Buy |
2,437,908
+91,232
| +4% | +$12.2M | 0.1% | 222 |
|
|
2023
Q1 | $360M | Sell |
2,346,676
-9,629
| -0.4% | -$1.59M | 0.13% | 166 |
|
|
2022
Q4 | $423M | Sell |
2,356,305
-92,509
| -4% | -$15.1M | 0.16% | 132 |
|
|
2022
Q3 | $290M | Sell |
2,448,814
-119,997
| -5% | -$18.2M | 0.11% | 200 |
|
|
2022
Q2 | $367M | Buy |
2,568,811
+196,408
| +8% | +$28.1M | 0.13% | 172 |
|
|
2022
Q1 | $409M | Buy |
2,372,403
+158,518
| +7% | +$26.7M | 0.12% | 179 |
|
|
2021
Q4 | $562M | Buy |
2,213,885
+70,143
| +3% | +$20.5M | 0.17% | 117 |
|
|
2021
Q3 | $825M | Buy |
2,143,742
+264,633
| +14% | +$97.6M | 0.27% | 71 |
|
|
2021
Q2 | $442M | Buy |
1,879,109
+339,067
| +22% | +$60.6M | 0.15% | 145 |
|
|
2021
Q1 | $202M | Sell |
1,540,042
-2,261
| -0.1% | -$328K | 0.08% | 306 |
|
|
2020
Q4 | $161M | Buy |
1,542,303
+62,990
| +4% | +$6.37M | 0.06% | 342 |
|
|
2020
Q3 | $105M | Buy |
1,479,313
+528,946
| +56% | +$36.9M | 0.05% | 409 |
|
|
2020
Q2 | $61M | Buy |
950,367
+775,540
| +444% | +$42.5M | 0.03% | 527 |
|
|
2020
Q1 | $5.2M | Sell |
174,827
-78,519
| -31% | -$1.81M | ﹤0.01% | 1147 |
|
|
2019
Q4 | $4.96M | Buy |
253,346
+179,048
| +241% | +$3.18M | ﹤0.01% | 1371 |
|
|
2019
Q3 | $1.18M | Buy |
74,298
+67,130
| +937% | +$992K | ﹤0.01% | 1922 |
|
|
2019
Q2 | $105K | Sell |
7,168
-50,421
| -88% | -$1.08M | ﹤0.01% | 2510 |
|
|
2019
Q1 | $1.17M | Sell |
57,589
-20,048
| -26% | -$372K | ﹤0.01% | 1916 |
|
|
2018
Q4 | $1.18M | Buy |
+77,637
| New | +$1.28M | ﹤0.01% | 1842 |
|
Other funds holding MRNA
TP
Legal & General Group's MRNA Position: Q2 2026 in Review
Legal & General Group increased its Moderna (MRNA) stake by 18% in Q2 2026, buying an estimated $6.84M and bringing the position to 883,075 shares worth $61.8M. The position accounts for 0.01% of the portfolio, ranked #602.
Legal & General Group first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $825M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Legal & General Group held 883,075 shares of Moderna worth $61.8M as of Q2 2026.
- Legal & General Group bought 132,234 Moderna shares in Q2 2026, an estimated $6.84M.
- Moderna made up 0.01% of Legal & General Group's portfolio in Q2 2026, its #602 holding.
- Legal & General Group first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
- Legal & General Group's Moderna position peaked at $825M in Q3 2021.
- 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.